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ABSTRACT
SYNTHESIS OF 4-AZIDOCOUMARINS AND THEIR USE IN
COPPER-CATALYZED AZIDE-ALKYNE CYCLOADDITION REACTIONS
By
Anthony J. Nesturi
Triazole-containing compounds have shown great biological activity
ranging from antiviral, antibacterial, to anticancer, to name a few. Coumarin
derivatives have also shown interesting biological activities. The combination of
these bioactive compounds appears to have great promise for new and future
medicines. In this work, various 4-azido-coumarins were synthesized via the
transformation of the 4-hydroxy derivatives to 4-benzotriazolyloxy coumarins
by

reaction

with

the

peptide

coupling

agent

(benzotriazol-1-yloxy)tris-(dimethylamino)phosphonium hexafluorophosphate
(BOP), and 1,8-diazabicycloundec-7-ene (DBU) as the base, in tetrahydrofuran
(THF) solvent.

The 4-benzotriazolyloxy coumarins were converted to the

4-azidocoumarins by reaction with sodium azide (NaN3), and the overall process
was simplified to a one-pot, two-step process. The methodology reduced the need
for additional manipulations and purifications. Using the 4-azidocoumarins thus
prepared,

the

1,4-disubstituted-1,2,3 triazoles

were

synthesized

copper-catalyzed alkyne-azide cycloaddition (CuAAC) reaction.

via

a

CuAAC

reactions of the azides were optimized by screening of various copper catalysts
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and copper tetrakis acetonitrile hexafluorophosphate ([Cu(CH3CN)4]PF6) gave the
best results in the experiments performed. Once the reaction conditions were
optimized, various 4-(1,2,3-triazolyl)coumarins were synthesized in good to
excellent yields.
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INTRODUCTION
The triazole moiety, as the name indicates, contains three nitrogen atoms
in a five-membered ring. As illustrated in Figure 1, there are two isomeric forms
of triazoles, namely the 1,2,3 and the 1,2,4 isomers.

Figure 1. The two isomers of triazoles.
Compounds containing these five-membered rings exhibit a wide range of
bioactivity.1

For example, the triazole containing compound in Figure 2 has

shown a wide spectrum of antifungal activity.2

This compound is a potent

antifungal with the ability to competitively inhibit the enzyme activity of
lanosterol 14α-demethylase (CYP51) in the demethylation step involved in the
biosynthesis of ergosterol.2 Ergosterol is an important constituent of the cell
membrane of fungi. This antifungal property makes the mentioned compound a
good agent to fight against the Candida species.

The antifungal effect was

observed with a minimal concentration range of 0.0625 to 1.0000 μg/mL, with
80% inhibition of growth of the various fungal pathogens tested.2

7

Figure 2. An antifungal compound containing the 1,2,4-triazole motif.
Pharmaceutical

companies

like

AstraZeneca

have

used

triazole

compounds in some of their antibacterial drugs. The utilizations of oxazolidinone
moieties in their antibacterial compounds produced great results against
gram-positive bacteria such as: methicillin-susceptible Staphylococcus aureus,
penicillin-susceptible Streptococcus pneumoniae, and Haemophilius influenzae.
The disadvantage of the oxazolidinone-derived product was its inhibitory effect
on Monamine Oxidase-A (MAO-A) activity, which leads to severe hypertensive
problems when the medication was used.3 To resolve this complication with the
oxazolidinone compound Reck et al. attached a 1,2,3-triazole group, and the
resulting compound (Figure 3) reduced the hypertensive problem produced by the
use of the medication. The use of the 1,2,3-triazole did not appear to affect the
antibacterial potency.3
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Figure 3. An oxazolidinone antibacterial compound with a 1,2,3-triazole, which
reduced MAO-A inhibition.
Triazole compounds have shown beneficial results in the fight against
diseases that have been difficult to eradicate.

Kumar et al. provided strong

evidence that quinoline triazolyl sugar compounds attacks Mycobacterium
tuberculosis H37Rv.4 They suggested the use of this compound as an effective
anti-tuberculosis agent. From the various synthesized quinoline triazolyl sugar
compounds.

The compound in Figure 4 showed the most promise, where

concentrations of 5 μg/mL and 25 μg/mL resulted in 76.41% and 78.37%
reduction in relative light units in the luciferase mycobacteriophage test,
respectively.4 In this test a plasmid is inserted into the bacterium by the phage
virus, which contains luciferase and ampicillin resistant genes. The ampicillin
resistance promotes the expression of the plasmid and with it luciferase is
synthesized by the mycobacteria, resulting in the observed light, which is
quantified to relative light units observed from the control and compound treated
bacterium.

The decreasing amount of light observed is correlated with the

anti-tuberculosis activity of the quinoline triazolyl sugar compound.4
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Figure 4. Triazole containing compound as an anti-tuberculosis agent.
The bioactivity benefits of the triazole moiety contribute vastly in the
creation of new bioactive compounds, and the added advantage that other
bioactive groups attached to it could lead to a great improvement in activity or in
the identification of novel activity.

For example, the antiviral compound

illustrated in Figure 5 contains a coumarin and a triazole moiety. This compound
performs very well through dual action as a protease and reverse transcriptase
inhibitor. 5 The compound provides a 92% inhibition of reverse transcriptase with
IC50 at 5.56 μM and 61% inhibition of protease activity with IC50 at 27.06 μM.5
The combined benefit gained by coumarin and triazole makes this compound a
very promising antiviral agent.

Figure 5. Very potent reverse transcriptase and protease inhibitor.
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The compound discussed above (Figure 5) is related to the subject of this
thesis, in that it contains 1,2,3-triazole linked to a coumarin moiety. The red
colored motif in Figure 5 is the coumarin and the blue is the 1,2,3-triazole ring.
Coumarin is in fact a benzopyrone and the name comes from the French word for
tonka bean “coumarou”.

Other natural sources, particularly plants such as

Murraya siamensis6 Toddalia asiatica7and Calophyllum lanigerum,8 and
Australian ascidians of the Didemnum species9 are a few sources of various
coumarin compounds.

Many coumarins have fascinating and significant

physiological as well as biological properties.

For example, the coumarins

isolated by Ito et al. show anti-tumor activities in the Epstein-Barr
virus-activation assay.6

This test measures the capability of the coumarin

compounds to inhibit the ability of the Epstein-Barr virus to cause cancer in
otherwise healthy cells.
Chen et al. have studied the use of coumarin derivatives as anticancer
agents.10

In this study an in vitro analysis of the compounds showed that

7-(6-chloropyridin-2-ylthio)-4-methyl-2H-chromen-2-one was a highly potent
compound with GI50 values ranging from 0.92 to 2.11 mM for differing cell lines
(Figure 6.). The compound promoted apoptosis and showed growth inhibitory
activity in cancer cells and only weak cytotoxicity to normal cells.10
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Figure 6. A coumarin derivative that promoted apoptosis of lung cancer cells.
In

a

skin

cancer

study

performed

by

Banerjee

et

al.,

4-methyl-7-hydroxycoumarin showed great ability in preventing the progression
of skin cancer when rats were exposed to 7,12-dimethylbenz[a]anthracene
(DMBA).11 A summary of the results from the publication of Banerjee et al.,
illustrated in a graph, is shown in Figure 7. The data clearly show that the
coumarin compound acted as an inhibitor of DMBA-mediated tumorigenesis.
The authors determined that the coumarin compound prevented the cancer cells
from entering the S phase of the DNA replication, ultimately leading to the
reduction the tumor formation in mice.11

Figure 7. Structures of DMBA and 4-methyl-7-hydroxycoumarin. Shown to the
right is the effect of 4-methyl-7-hydroxycoumarin on the progression of skin
cancer in mice (graph taken from reference 11).
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Further studies on breast cancer have shown that high levels of estrogen
synthesis are associated with the formation of tumors.

The aromatase and

sulfatase pathways involved in the synthesis of the estrogen, are linked to the
formation of tumors. Studies in the chemotherapy of breast cancer have shown
that coumarin analogs and their 7-hydroxycoumarin lower the activity of the
sulfatase and aromatase enzymes. This action inhibits the synthesis of estrogen,
which has been linked to one third of breast cancer cases.12 Figure 8 shows the
structures of the two coumarin derivatives which are known to possess this novel
anticancer activity.12

Figure 8. Aromatase and sulfatase activity inhibiting coumarin compounds.
Compounds that combine the coumarin and triazole moieties have been
reported in many publications. Other examples 3-(1,2,3-triazolyl)coumarins and
4-(1,2,3-triazolyl)coumarins have been previously synthesized13 and studied for
their fluorescent properties and for their use in protein14 or DNA labeling.15 The
labeling of protein and DNA by this metal-catalyzed cycloaddition greatly
facilitated this process. These reactions can be run in some part of aqueous
solvent, making it possible to incorporate fluorophores in great yield into water

13

soluble protein without compromising their structural integrity. The CuAAC
method has provided various oligonucleotides that are synthesized under mild
conditions and easily incorporated in DNA.

Figure 9. Shown to the left is a protein labeled with a fluorescent coumarin probe
(figure taken from reference 14). Shown to the right is thymine labeled with a
3-(1,2,3-triazoyl)-coumarin fluorescent probe for DNA labeling (redrawn from
reference 15).
The 1,2,4-triazolyl coumarin shown in Figure 10 has shown good
antibacterial and antifungal properties.16

The antibacterial properties were

comparable to streptomycin against Bacillus subtilis, Escherichia coli, and
Pseudomonas aeruginos.16 The compound’s antifungal activity is similar to that
of fluconazole against fungal cultures of Aspergillus niger and Aspergillus
flavus.16

Figure 10. Potent antibacterial triazole-coumarin conjugate.
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A 1,2,3-triazole containing two coumarin moieties (Figure 11) presented
significant antimycobacterial activity as against Mycobacterium tuberculosis,
similar to streptomycin. This compound is also active against gram-positive
bacteria, however, it was not as effective when compared to streptomycin and
fluconazole.17

Figure 11. Antibacterial, antiviral, and antitubercular 1,4-disubstituted
bis-coumarin triazole derivative.
As can be seen from the foregoing, not only are triazoles and coumarins
independently important biologically, but a combination of the two moieties also
leads to powerful biologically valuable compounds.

Thus, we were highly

interested in combining the biological properties of the triazolyl moiety with that
of coumarin to generate a novel class of “triazolyl coumarins”. We chose to
prepare C-4 triazolyl coumarins with the general structure shown in Figure 12.
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Figure 12. C-4 triazolyl coumarins that were selected for synthesis.
Two possible retrosynthetic analyses of the structural prototype depicted
in Figure 12 are shown in Scheme 1. In one approach (shown to the right in
Scheme 1), a leaving group at the C-4 position of coumarin can potentially be
displaced with a triazole. This however, could result in the formation of N1 and
N2 regioisomeric products.

In addition, the generality and ease of such a

displacement with a triazole as nucleophile is unknown.
Scheme 1. Two possible approaches to the synthesis of C-4 triazolyl coumarins

As shown to the left of Scheme 1, an alternate approach is a dipolar
cycloaddition of a C-4 azidocoumarin derivative with an alkyne. This appeared to
be a methodology that could be more readily accomplished, with complete control
over regiochemical questions. Specifically, the coumarin would be attached to
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the N1 of the triazole and the triazolyl substituent would be positioned at the C-4
of the coumarin. Further, a variety of approaches are available for the synthesis
of terminal alkynes, e.g. Sonogashira reactions of aryl halides, Corey-Fuchs
olefination of aldehydes followed by reaction with a strong base, and the
Bestmann-Ohira alkynylation of aldehydes, which provide ready access to almost
any alkyne.
This leaves only the development of a general method for the synthesis of
4-azidocoumarins. A potential procedure for accomplishing this, on the basis of
chemistry developed in our laboratories, is described later in this chapter.
Synthesis of 1,2,3-Triazoles
The classical method for the synthesis of the triazole ring is via a Huisgen
ligation, which is a 2,3-dipolar cycloaddition between an alkyne and an azide.
This reaction involves the 4π electrons of the zwitterionic azide, the dipole, and
the 2π electrons of a neutral dipolarophile, the alkyne, resulting in a
five-membered ring.18 The reaction occurs by the interaction of the HOMO of the
dipole with the LUMO of the dipolarophile. Figure 10 shows three different types
of interactions of the dipole-dipolarophile electron densities. The reaction types
categorized by Huisgen are as follows.
(a) Type 1: is a normal electron-demand type of process wherein the high-lying
HOMO (ψ2) of the dipole interacts with the LUMO (ψB) of dipolarophile.
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(b) Type 2: due to the similar energy gap, either the HOMO of the dipole interacts
with the LUMO of the dipolarophile, or the LUMO of the dipole can interact
with the HOMO of the dipolarophile.
(c) Type 3: is the inverse-electron demand type of reaction, where the low-lying
LUMO of the dipole (ψ3) interacts with the HOMO (ψA) of the dipolarophile.

Figure 13. HOMO and LUMO interactions between the dipole and dipolarophile
(redrawn from ref 18).
One major problem with the otherwise highly atom-economical Huisgen ligation
is the propensity for the formation of regioisomeric triazoles via the
cycloaddition.

Thus,

under

thermal

conditions,

both

1,4-

and

1,5-disubstituted-1,2,3-triazoles are formed in the Huisgen ligation (Scheme 2).
Scheme 2. Formation of regioisomeric products in the Huisgen ligation
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In 2002, Meldal and colleagues,19 as well as Fokin, Sharpless, and
colleagues,20 independently demonstrated a metal-catalyzed version of the
Huisgen ligation, that was highly regioselective. In the copper-catalyzed reaction,
the use of a copper(I) catalyst largely eliminated the formation of the
1,5-disubstituted 1,2,3-triazoles in the reaction of azides with alkynes.

The

general term “click chemistry” was coined by Sharpless and coworkers due to the
fact that high-energy groups (azide and alkyne) combine to form a stable, lower
energy compound. The copper-catalyzed reaction of azides with alkynes is now
called CuAAC (Copper (I) catalyzed Alkyne-Azide Cycloaddition). Generally,
the CuAAC reactions utilize an in-situ reduction of copper(II) to copper(I), or a
copper(I) salt, and organic solvent-soluble copper salts such as [Cu(CH3CN)4]PF6
can also be used.20
The proposed mechanism for the CuAAC reactions postulated by Fokin
et al.21 is shown in Figure 14. The alkyne in the reaction reversibly coordinates
through a weak π bond with the copper catalyst. In the following step another
molecule of copper catalyst forms a σ bond with the alkyne.

The azide

coordinates with the π bound copper, and this is followed by a nucleophilic attack
at the N3 of the azide resulting in a C–N bond. The dinuclear copper intermediate
proceeds rapidly to the formation of the triazolide by the oxidation of one of
copper atoms with the stabilizing effect of the other copper atom.

Finally,

detachment of the copper catalyst is facilitated by a proton donor, forming the
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desired 1,4-disubstituted 1,2,3-triazole. The catalytic cycle proceeds until the
depletion of the reactants.

Figure 14. Catalytic cycle proposed by Fokin et al. for Cu(I) azide alkyne
cycloaddition (ref 21).
Synthesis of 4-Azidocoumarins
A variety of 4-hydroxycoumarins are commercially available or are easily
synthesized.22–24 The C-4 hydroxyl group in these compounds can be converted
to a leaving group and then subjected to displacement with azide ion to yield
4-azidocoumaris. A variety of leaving groups are known at the C-4 position of
coumarins (Scheme 3), and commonly the chloride and sulfonate derivatives of
coumarin can be prepared.25–27
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Scheme 3. Coumarin derivatives with leaving groups at the C-4 position

In fact, both types of reactive coumarin derivatives have been used for the
synthesis of a variety of 4-azidocoumarin derivatives.27

However, these

approaches require two discrete steps, namely synthesis of the reactive coumarin
derivative and a subsequent displacement with azide ion.

Furthermore the

halogenation procedure involves the reflux of 4-hydroxycoumarin in POCl3 and
the formation of a modest product yield with a byproduct formation that requires
azeotropic distillation to finally separated the products.25
Scheme 4. Chlorination of 4-hydroxycoumarin

Research in Prof. Lakshman’s laboratories28 and from chemists at
Weyth,29 has led to the identification of a novel method for the activation of
amide linkages. Specifically, Lakshman and Bae have demonstrated that reaction
of

inosine

and

deoxyinosine

with

21

the

peptide-coupling

agent

(1H-benzotriazol-1-yloxy)tris(dimethylamino)phosphoniumhexafluorophosphate
(BOP) leads to the formation of O6-(benzotriazol-1-yl) nucleoside analogues
(Scheme 5).28
Scheme 5. Synthesis of O6-(benzotriazol-1-yl) nucleoside derivatives

Subsequently, researchers at Weyth have demonstrated similar results.29
Importantly, in their work they have generated 4-aminoquinazoline by activation
of 4(3H)-quinazolinone using BOP. What should also be noted is that both
inosine and 4-hydroxyquinazoline can be subjected to activation with BOP and
nucleophilic displacement in a one-pot process as proposed by the authors.29
Scheme 6. Synthesis of 4-aminoquinazoline

These benzotriazolyl intermediates are reactive towards nucleophilic
displacement.

Notably, of relevance to the chemistry herein, Singh and
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Lakshman have prepared azido nucleosides from the O6-(benzotriazol-1-yl)
nucleosides in a two-step operation as shown in Scheme 7.30
Scheme 7. O6-(benzotriazol-1-yl) nucleosides and their use in the synthesis of
1,2,3-triazole nucleosides

We therefore reasoned that reaction of 4-hydroxycoumarin with BOP and
a suitable base, in a suitable solvent, should yield the benzotriazolyl ether of the
coumarin. Whether or not this intermediate is isolable can only be determined
only upon performing the reaction. Secondly, on the basis of prior results, it
should be eminently possible to synthesize 4-azidocoumarins in a two-step,
one-pot procedure as shown in Scheme 8.
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Scheme 8. A potential, simple one-pot method for the synthesis of
4-azidocoumarins

Deprotonation of the hydroxycoumarin by a base should yield a
resonance-stabilized enolate. This species can react at the phosphorus atom of
BOP, with loss of the benzotriazolyloxy anion, as has been demonstrated
previously for nucleosides and pyrimidinones.28, 29 The formed benzotriazolyloxy
anion

can

then

addition-elimination

displace
pathway,

hexamethylphosphoramide
leading

to

the

(HMPA),

potentially

via

isolable

an
C-4

benzotriazolyloxy coumarin derivative. This species can be converted to the
azido coumarin, via another addition-elimination reaction. This step can either be
performed on the isolated C-4 benzotriazolyloxy coumarin or via an in situ
displacement, subsequent to formation of C-4 benzotriazolyloxy coumarin.
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Once the 4-azidocoumarins become available, they can be used in CuAAC
reactions with various alkynes, leading to C-4 triazolylcoumarins. As stated in
the introduction, triazoles and coumarins are both physiologically very important.
Thus, development of synthetic methodology for combining these two structural
motifs into a new class of 4-(4-substituted-1H-1,2,3-triazolyl)coumarins could
result in compounds that are inherently biologically active.

We not only

anticipate an understanding of the chemistry involved and an evaluation of the
broad utility of the method, but we also expect to evaluate any potential
anti-cancer and antiviral properties of the newly developed compounds (via
collaborations) as well as mechanistic questions and other properties.
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RESULTS AND DISCUSSION
As described in the introduction the azidization of 4-hydroxycoumarin
was performed by a two-step one-pot reaction.
was

converted

to

its

benzotriazolyl

Briefly, 4-hydroxycoumarin
ether

by

reaction

with

(benzotriazol-1-yloxy)tris(dimethylamino)phosphoniumhexafluorophosphate
(BOP) in the presence of a base, and the newly synthesized benzotriazolyl ether
was then converted to the azide. The reaction and the results are summarized in
Table 1.

For the first step of the reaction tetrahydrofuran (THF) and

1,2-dimethoxyethane

(DME)

were

evaluated

1,8-diazabicycloundec-7-ene (DBU) as the base.
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as

solvents

with

Table 1. The results of the various atempts in the azidization of
4-hydroxycoumarin

Entry Solvent 1

Solvent 2

Additive

Amount
of
Additive
10 mol%

1

THF

None

18-Cr-6

2

THF

None

18-Cr-6

3

THF

None

Diglyme

20 mol%

4

DME

None

None

None

5

DME

Diglyme

None

None

6

THF

EtOH

None

None

5 mol%

Result, Time
95% Isolated yield
Step 1 reaction time 2 hours
Step 2 reaction time 24 hours
80% Isolated yield
Step 1 reaction time 2 hours
Step 2 reaction time 72 hours
Formation of the
benzotriazolyl ether occurred
but azidation was not
observed
Rapid formation of the
benzotriazolyl ether occurred
but azidation was not
observed
80% Isolated yield
Step 1 reaction time 1 hours
Step 2 reaction time 24 hours
90% Isolated yield
Step 1 reaction time 2 hours
Step 2 reaction time 24 hours

The azidization step was performed after formation of the coumarin
benzotriazoyl ether and this occurs by an addition-elimination reaction with azide
anion as the nucleophile. In the first attempt 10 mol% of 18-crown-6 (18-Cr-6)
was used as shown in entry 1 in Table 1 18-Cr-6 ether is a phase-transfer catalyst,
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which facilitates the solubility of sodium azide in organic solvents by solvation of
the sodium cation (Na+).

However, crown ethers are relatively expensive

compounds and in the process of purification they can contaminate the product in
the case of an inefficient separation. However, this reaction proceeded well and
gave 4-azidocoumarin in 95% isolated yield. In attempt to reduce the amount of
crown ether, 5 mol% of 18-Cr-6 ether was used in a subsequent reaction (entry 2
of Table 1), but this resulted in significantly slower reaction (step 2 took
72 hours) and a product yield of 80%. In entry 3, the same solvent system as in
entry 2 was used, but 20 mol% of bis(2-methoxyethyl) ether was added to the
azidation step (step 2) after the formation of the benzotriazolyl ether. This effort
did not prove fruitful in the azidization step.

Other attempts were directed

towards removal of 18-Cr-6 from the azidization step via the use of other dry
solvents. DME and diglyme were used in an attempt to replace the crown ether
due to their potential cation-chelating abilities. In entry 4, use of DME provided a
very fast reaction leading to the benzotriazolyl ether formation (1 hour for step 1).
However, the azidization step did not occur in this solvent in a 24 hour period. In
entry 5 the benzotriazolyl ether formation was performed in DME solvent, the
solvent was evaporated and diglyme was added as a solvent for the azide-forming
step. The step 2 of the reaction was run for 24 hours and yielded 80% of the
isolated product. Although diglyme was reasonable, its high boiling point and
miscibility with organic solvent such as CH2Cl2 made it tedious to remove from
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the reaction mixture. For example in our workup we employed EtOAc as the
organic solvent for extraction, and 300 mL solution containing of brine and water
mixture at 3:7 respectively for separation. Other difficulties could be present with
the solubility of the substituted coumarins in EtOAc. To remedy these difficulties
another option was evaluated. A web search led to the understanding that sodium
azide is soluble in ethanol at 0.316 g/100 mL (at 16 °C).32 Thus, in entry 6 the
formation of the benzotriazole ether was conducted in THF, then an equal volume
of anhydrous ethanol was added followed by the addition of sodium azide into the
reaction mixture. With these changes, the azide forming reaction was complete
within 24 h and gave a 90% isolated yield of 4-azidocoumarin.
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Table 2. Results of the azidation reactions of various coumarins.a

Entry RX#
R1
R2
R3
Yield
1
74B
H
H
H
95%
2
84B
Br
H
H
93%
3
85B
Cl
H
H
99%
4
86B
Cl
H
Cl
80%
5
88B
Me
H
H
71%
6
89B
H
Me
H
72%
7
90B
H
MeO
H
86%
a
The benzotriazole ether step in all reactions was conducted for 2 hours at room
temperature followed by overnight azidization.

The method developed and described above for the azidization of the
4-hydroxycoumarin (Table 1) provided us with a protocol for the formation of
other substituted 4-azidocoumarin derivatives. The results are summarized in
Table 2, where the various 4-hydroxycoumarins in entries 1 to 7 have gave good
to excellent yields of the corresponding azido derivatives, ranging from 71–99%.
Of particular importance is the need for effective mixing during the course of
these reactions. Specifically, great care and consideration should be given to the
azidization step. Inadequate mixing gave poor yields, approximately 50%, when
reactions were performed in screw cap vials. The impedance to good mixing was
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caused by the formation of an insoluble gelatinous texture of the reaction mixture
in the azidization step. Use of round bottom flasks provided superior results. The
six azidocoumarins synthesized were obtained in good yields after column
chromatography and were then used in the azide-alkyne click reactions.
Initially, the click reactions were performed by using the copper sulfate
(CuSO4)/sodium ascorbate as the catalyst system originally reported by Sharpless
and coworkers (entries 1 through 8).21 In this method CuSO4, is reduced in situ
by sodium ascorbate. However, the solvent system employed for entries 1–4 in
Table 3 was CH2Cl2/H2O, the reactions were performed at room temperature and
at 50 °C with no substantial differences observed by TLC (incomplete reactions
with only about 50% product formation). The solvent system in entries 5 and 6
consisted of an ethanol–water mixture, and no product formation was observed.
Similarly, use of t-butanol and water as the solvent system with CuSO4/sodium
ascorbate at room temperature or at 50 oC did not result in product formation
(entries 7 and 8). Next, the catalytic system was changed from CuSO4/sodium
ascorbate to copper(II) chloride (CuCl2)/sodium ascorbate as shown in entries 9
and 10. Reactions were conducted both at room temperature and at 50 °C, and the
solvent system was also changed to THF/H2O. At the elevated temperature of
50 °C a small amount of product formation (ca 10 %) was observed by TLC. Due
to the observed no to low conversions with the inorganic copper-catalyzed
reactions, the use of organic copper(I) salts were evaluated.
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In entry 11,

effectiveness of copper(I) thiophene-2-carboxylate in CH2Cl2/CH3OH was
evaluated 50 °C. This reaction gave very good yield (entry 11). Nonetheless, we
encountered the formation of a small amount of the isomeric 1,5-triazole as
shown by NMR in Figure 15 (small peak at 6.35 ppm).

Figure 15. NMR spectrum of copper(I) thiophene-2-carboxylate catalyzed
reaction with products of 1,4 and traces of 1,5-(1,2,3-triazoyl)-coumarin (circled
by the oval).
A NOESY experiment of the 1,5-triazoyl isomer was performed and the
data is illustrated in Figure 16. The data shows that there is no spatial correlation
observed between the triazoyl and the vinyl protons.

This supports the

1,5-disubstitution pattern. In this isomer the vinyl proton not spatially proximal to
any other proton, especially the vinyl proton.
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Figure 16. NOESY spectrum in CDCl3 of 4-(5-phenyl-1H-1,2,3-triazol-1-yl)coumarin showing no correlation with any protons and especially the vinyl
proton.
Similar to the 1,5-disubstituted triazolyl coumarin, a NOESY experiment
was conducted on the 1,4-triazoyl isomer and this is shown in Figure 17. In this
spectrum a clear interaction of the vinyl proton at 6.35 ppm with the triazoyl
proton at 7.99 ppm is seen, and this is indicated by the lines.
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Figure 17. NOESY spectrum in CDCl3 of 4-(4-phenyl-1H-1,2,3-triazol-1-yl)coumarin clearly showing the correlation between the vinyl and triazolyl protons
(conformer shown).
The use of copper(I)-thiophene-2-carboxylate presented the possibility to
use another organic Cu catalyst, namely tetrakis (acetonitrile) copper(I)
hexafluorophosphate [Cu(CH3CN)4]PF6 under the same reaction conditions as
with

Cu(I)

thiophene-2-carboxylate

(entry

12).

A

reaction

with

[Cu(CH3CN)4]PF6 resulted in a product yield of 95%, and the NMR showed
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formation of only the 1,4-triazole regioisomer. In entry 13, the exact reaction
conditions used by Qian Wang et al.13 were attempted for our reaction. The
reactions reported by Wang et al. involve the CuAAC reactions of
3-azidocoumarin derivatives with 5% CuSO4/10% sodium ascorbate in ethanol
and water.13 Although they report a single example of the use of 5% CuSO4/10%
sodium ascorbate in ethanol and water, use of these conditions for the CuAAC
reaction of 4-azidocoumarin and 1-ethynylbenzene did not effectuate any product
formation in our hands (as evaluated by NMR, Figure 18).

Figure 18. Crude mixture of a reaction between 4-azidocoumarin and
1-ethynylbenzene with 5% CuSO4/10% sodium ascorbate as the catalyst in
ethanol and water after workup showing no formation of triazole.
In entry 14, a reaction with copper(I) iodide as catalyst in acetonitrile and
water was performed at 50 °C, and only a low extent of product formation was
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observed (ca 10–25%), as observed by TLC. Due to the low conversion observed
in entry 14, the solvent system was evaporated and replaced with CH2Cl2/CH3OH
(entry 15). Still, this was not effective either. Use of copper(I) chloride in
CH2Cl2/CH3OH again showed low conversion to product (ca 10–25%), and at
50 °C (entry 16) no significant change was observed. The low yielding reaction
prompted another change of the solvent system (entry 17), and in CH3CN/CH3OH
at 50 °C, as a light improvement was observed but conversion still remained
(ca 20–30%), as observed by TLC.
In summary, [Cu(CH3CN)4]PF6 proved to be the best among the catalytic
systems tested in Table 3. Product formation occurred in high yield and no trace
of the isomeric 1,5-triazole was observed by NMR. Reactions were performed in
CH2Cl2/CH3OH, which offered good solubility for all the azidocoumarin as well
as the catalyst. Addition of CH3OH was used to ensure the presence of a proton
source for the recycling of the catalyst.
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Table 3. Various conditions tested for the CuAAC reaction of 4-azidocoumarin
with phenylacetylenea

Entry

Catalyst
5 mol % CuSO4
10 mol % sodium ascorbate
5 mol % CuSO4
10 mol % sodium ascorbate
5 mol % CuSO4
10 mol % sodium ascorbate
5 mol % CuSO4
10 mol % sodium ascorbate
12 mol % CuSO4
24 mol % sodium ascorbate
12 mol % CuSO4
24 mol % sodium ascorbate
12 mol % CuSO4
24 mol % sodium ascorbate
12 mol % CuSO4
24 mol % sodium ascorbate
33.5 mol % CuCl2
6.7 mol % Sodium Ascorbate
33.5 mol % CuCl2
6.7 mol % sodium ascorbate
10 mol %
Copper(I)-thiophene-2-carboxylate

Solvent System
Condition
Yield
DCM 0.33 mL
1
rt, 24 h
~40-50%
H2O 0.3 mL
DCM 0.33 mL
2
50 °C, 24 h
~40-50%
H2O 0.3 mL
DCM 0.66 mL
3b
rt, 24 h
~40-50%
H2O 0.6 mL
DCM 0.66 mL
4b
50 °C 24 h
~40-50%
H2O 0.6 mL
Ethanol 0.66 mL
5b
rt, 24 h
No Product
H2O 0.6 mL
Ethanol 0.66 mL
6b
50 °C, 24 h
No Product
H2O 0.6 mL
t-Butanol 0.66 mL
7b
rt, 24 h
No Product
H2O 0.6 mL
t-Butanol 0.66 mL
8b
50 °C, 24 h
No Product
H2O 0.6 mL
THF 0.53 mL
9b
rt, 24 h
No Product
H2O 0.12 mL
THF 0.53 mL
10b
50 °C, 24 h
~10-25%
H2O 0.12 mL
CH2Cl2 0.55 mL
100%
11b
50 °C, 24 h
CH3OH 0.12 mL
conversionc
CH2Cl2 0.55 mL
12b
10 mol % [(CH3CN)4Cu]PF6
50 °C, 24 h
95% Yieldd
CH3OH 0.12 mL
20 mol % CuCl2
Ethanol 2.5 mL
13b
rt in dark, 24 h
No producte
20 mol % sodium ascorbate
H2O 2.5 mL
CH3CN 0.47 mL
14b
20 mol % CuI
50 °C, 24 h
~10-25%
H2O 0.15 mL
DCM 0.55 mL
15b
20 mol % CuI
50 °C, 24 h
~10-25%
CH3OH 0.12 mL
DCM 0.55 mL
16b
20 mol % CuCl
50 °C, 24 h
~10-25%
CH3OH 0.12 mL
CH3CN 0.55 mL
17b
20 mol % CuCl
50 °C, 24 h
~20-30%
CH3OH 0.12 mL
a
b
c
Reaction were run at 0.1 mmol scale. Reaction were run at 0.2 mmol scale. Not isolated yield TLC only
andcrude mixture 1H NMR confirmed. dIsolated yield. eAnalysed by 1H NMR, and reaction performed based
on literature procedure from reference 7.
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The reaction conditions involving the use of [(CH3CN)4Cu]PF6 performed
very well on all five alkynes that were tested in reactions with 4-azidocoumarin
(Table 4), with yields in the range of 72–95%. The only notable exceptions are
shown in entries 3 and 4, involving the reactions of 1-ethynyl-4-methoxybenzene
and 3-ethynylpyridine.

The reaction of 1-ethynyl-4-methoxybenzene was

incomplete after 24 hours at 50 °C. To remedy this problem the reaction was
re-run at 80 °C for 24 hours, which resulted in a product yield of 80%. The
reaction of 3-ethynyl-pyridine went to completion at room temperature with a
product yield of 95%.
Table 4. Alkynes used and conditions, and product yields in the CuAAC
reactions of 4-azidocoumarina

Entry
1

Alkyne

Yielda
95%

2

87%

3

80%b

4

95%c

a

Procedure: 0.2 mmol reaction in 0.55 mL of CH2Cl2 and 0.12 mL of CH3OH at
50 °C for 24 h with 10 mol % of [Cu(CH3CN)4]PF6. bReaction was performed at
80 °C. cReaction was performed at room temperature.
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The reaction conditions used for the conversions of 4-azidocoumarin to
the 4-(1,2,3)-triazolyl coumarins shown in Table 4 were then tested with the six
substituted 4-azidocoumarins, and the results are listed in Table 5. The overall
reactivity of the substituted coumarin compounds remained unchanged.

As

reported for the reaction of 4-azidocoumarin with 1-ethynyl-4-methoxybenzene, a
similar reactivity problem was encountered in the reaction of 7-methoxycoumarin
with 1-ethynyl-2-methyl-4-methoxybenzene (entry 4).

By TLC analysis, this

reaction showed only a low extent of product formation. When the reaction
temperature was raised to 80 °C for another 24 hours, TLC showed formation of
new uncharacterized materials indicating possible decomposition.
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Table 5. Various alkynes and azidocoumarin combinations in diverse CuAAC
reactionsa

R1

R2

R3

Yield

1

Br

H

H

67%

2

Me

H

H

86%

3

H

Me

H

89%

4

H

MeO

H

10-20%b

Entry

R

a

Procedure: 0.2 mmol reaction in 0.55 mL of CH2Cl2 and 0.12 mL of CH2Cl2 at
50 °C over 24 h using10 mol % of [Cu(CH3CN)4]PF6. bProduct formation is
tracked by TLC only.
Further

is

necessary

optimization

of

at

least

to

yields.

In

improve

some

of

this

aspect

these
the

reactions
use

of

tris(3-hydroxypropyltriazolylmethyl)amine and the use of 2,6-lutidine has been
described by Sharpless et al,20 however, further experiments are needed to see if
such additives will provide an improvement in the yields.
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EXPERIMENTAL SECTION
General Experimental Considerations
Thin layer chromatography was performed on aluminum foil-backed TLC
plates of 200 μm thickness and were visualized under short wavelength (265 nm)
and/or long wavelength (354 nm) ultraviolet light.

Column chromatographic

purifications were performed on 200–300 mesh silica gel. Tetrahydrofuran (THF)
solvent was distilled over lithium aluminum hydride (LiAlH4) then stored over
sodium metal (Na). It was then refluxed for at least one hour over sodium and
distilled prior to use. CH2Cl2 was distilled over CaCl2, and redistilled prior to use.
Ethyl acetate (EtOAc) was distilled prior to use. All other reagents were obtained
from commercial sources and were used without further purification. Proton
NMR spectra were recorded at 500 MHz in CDCl3 and are referenced to the
residual solvent resonance. Carbon NMR spectra were recorded at 125 MHz in
CDCl3 and are referenced to the residual solvent resonance.
General procedure for the conversion of 4-hydroxycoumarin derivatives to the
intermediateO4-(1,2,3-benzotriazolyl)

derivatives,

and

then

to

the

4-azidocoumarins.
The conversions of various 4-hydroxycoumarin derivatives (R1=H, R2=H,
R3=H) to the intermediate O4-(1,2,3-benzotriazolyl) derivatives and then the
azides were conducted in a two-step, one-pot process.
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As a representative

procedure,
equipped
(1.00 g,

into
with

a
a

5.09 mmol)

200 mL
stirring
in

THF

oven-dried
bar,
(50

was
mL)

round
placed

to

give

bottom

flask

4-hydroxycoumarin
a

0.1 M

solution.

1H-Benzotriazol-1-yloxy)tris(dimethylamino)phosphoniumhexafluorophosphate
(BOP, 2.65 g, 6.00 mmol, 1.2 equiv) was added and the mixture was stirred at
25 °C for 10 minutes. At this stage a white solid persists at the bottom of the
flask. Next DBU (0.91 mL, 6.04 mmol, 1.2 equiv) was added at which point the
mixture became homogenous, and turned to a slight yellow solution. The mixture
was stirred at room temperature until completion, generally 2 h, although the
course of the reaction was intermittently followed by TLC (SiO2/30% EtOAc in
hexanes) until it ended.

The reaction mixture was added NaN3 (0.66 g,

10.0 mmol, 2 equiv) followed by the addition of EtOH (200 proof, 50 mL). The
mixture was allowed to stir for 24 h at room temperature, and the course of
product formation was intermittently monitored by TLC (SiO2/30% EtOAc in
hexanes). Upon completion of the reaction, the mixture was partitioned between
CH2Cl2 and brine.

The organic layer was separated, dried over anhydrous

Na2SO4, and transferred into a round bottom flask. To this 200–300 mesh silica
gel was added and the solvent was evaporated under reduced pressure. The silica
gel with the adsorbed reaction mixture was loaded onto a 200–300 mesh silica gel
column and eluted with a mixture of EtOAc in hexanes. Fractions containing
pure material were combined, evaporated under reduced pressure, and vacuum
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dried.

All azidocoumarins were synthesized in a similar manner and any

deviations from this procedure are noted under the individual compound
headings.
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4-Azidocoumarin (1). Chromatography using 10–20% EtOAc in hexanes gave
889 mg (95% yield from a 5 mmol reaction) of compound 1 as a
light yellow solid. Rf (SiO2/30% EtOAc in hexanes) = 0.37.
Melting point = 155–157 °C dec (lit.33 154–155 °C).

1

H NMR

(500 MHz, CDCl3): δ 7.72 (d, 1H, Ar-H, J = 7.8 Hz), 7.60 (t, 1H, Ar-H,
J = 8.3 Hz), 7.35 (d, 1H, Ar-H, J = 8.3 Hz), 7.30 (t, 1H, Ar-H, J = 7.6 Hz), 6.14
(s, 1H, =C-H).

13

C NMR (125 MHz, CDCl3): δ 160.5, 153.6, 153.4, 133.2, 124.3,

123.4, 116.9, 114.8, 100.2. HRMS (ESI/TOF): calcd for C9H6N3O2 [M + H]+
188.0455, found 188.0451.
4-Azido-6-chlorocoumarin (2). Chromatography using gradient elution with
10–20% EtOAc in hexanes gave 219 mg (99% yield from a
1 mmol reaction) of compound 2 as a white solid.
Rf (SiO2/30% EtOAc in hexanes) = 0.44.
point = 169–171 °C dec.

1

Melting

H NMR (500 MHz, CDCl3): δ 7.69 (d, 1H, Ar-H,

J = 2.4 Hz), 7.53 (d, 1H, Ar-H, J = 8.8 Hz), 7.29 (d, 1H, Ar-H, J= 8.8 Hz), 6.16
(s, 1H, =C-H).

13

C NMR (125 MHz, CDCl3): δ 158.6, 152.1, 147.9, 133.12,

129.6, 122.9, 121.6, 116.78, 101.3. HRMS (ESI/TOF): calcd for C9H5ClN3O2
[M + H]+ 222.0065, found 222.0062.
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4-Azido-6-bromocoumarin (3). Chromatography using gradient elution with
15–20% EtOAc in hexanes gave 247 mg (93% yield from
a1 mmol reaction) of compound 3 as a white solid.
Rf (SiO2/30% EtOAc in hexanes) = 0.48.

Melting

point = 171–172 °C dec. 1H (500 MHz, CDCl3): δ 7.85 (d, 1H, Ar-H, J = 2.4 Hz),
7.68 (dd, 1H, Ar-H, J = 2.2, 9.0 Hz), 7.24 (d, 1H, Ar-H, J = 8.8 Hz), 6.15 (s, 1H,
=C-H).

13

C NMR (125 MHz, CDCl3): δ 160.2, 152.7, 152.6, 136.3, 126.3, 119.0,

117.4, 116.6, 101.2.

HRMS (ESI/TOF): calcd for C9H5BrN3O2 [M + H]+

265.9560, found 265.9563.
4-Azido-6-methylcoumarin (4). Chromatography using gradient elution with
10–20% EtOAc in hexanes gave 143 mg (71% yield from
a1 mmol reaction) of compound 4 as a white crystalline solid.
Rf (SiO2/30%

EtOAc

in

point = 171–172 °C dec. (lit.33 140–142 °C).

hexanes)
1

=

0.57.

Melting

H (500 MHz, CDCl3): δ 7.44 (s,

1H, Ar-H), 7.35 (d, 1H, Ar-H, J = 8.3 Hz), 7.18 (d, 1H, Ar-H, J = 8.3 Hz), 6.05 (s,
1H, =C-H), 2.37 (s, 3H, CH3).

13

C NMR (125 MHz, CDCl3): δ 160.7, 153.2,

151.6, 134.1, 134.1, 122.9, 116.6, 114.4, 100.0, 20.8. HRMS (ESI/TOF): calcd
for C10H8N3O2 [M + H]+ 202.0611, found 202.0633.
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4-Azido-7-methylcoumarin (5). Chromatography using gradient elution with
10–20% EtOAc in hexanes gave 145 mg (72% yield from a
1 mmol reaction) of compound 5 as a white solid.
Rf (SiO2/30%

EtOAc

in

point = 160–162 °C dec. (lit.33 155–156 °C).

hexanes)
1

=

0.46.

Melting

H (500 MHz, CDCl3): δ 7.58 (d,

1H, Ar-H, J = 8.3 Hz), 7.14 (s, 1H, Ar-H, J = 7.1 Hz), 7.10 (d, 1H, Ar-H,
J = 8.3 Hz), 6.06 (s, 1H, =C-H), 2.46 (s, 3H, CH3).

13

C NMR (125 MHz, CDCl3):

δ 160.8, 153.6, 153.4, 144.6, 125.5, 122.9, 116.9, 112.3, 99.0, 21.7. HRMS
(ESI/TOF): calcd for C10H8N3O2 [M + H]+ 202.0611, found 202.0637.
4-Azido-7-methoxycoumarin (6). Chromatography using gradient elution with
10–20% EtOAc in hexanes gave 187 mg (86% yield from a
1 mmol reaction) of compound 6 as a light red solid.
Rf (SiO2/30% EtOAc in hexanes) = 0.40.
point = 173–175 °C dec. (lit.33 178–180 °C).

1

Melting

H (500 MHz, CDCl3): δ 7.60 (d,

1H, Ar-H, J = 8.8 Hz), 6.85 (dd, 1H, Ar-H, J = 2.0, 9.0 Hz), 6.82 (d, 1H, Ar-H,
J = 2.4 Hz), 5.98 (s, 1H, =C-H), 3.88 (s, 3H, OCH3).

13

C NMR (125 MHz,

CDCl3): δ 163.9, 161.1, 155.5, 153.6, 124.4, 112.5, 108.2, 100.5, 97.0, 55.7.
HRMS (ESI/TOF): calcd for C10H8N3O3 [M + H]+ 218.0560, found 218.0564.
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4-Azido-6,8-dichlorocoumarin (7). Chromatography using gradient elution with
15–20% EtOAc in hexanes gave 205 mg (80% yield from a
1 mmol reaction) of compound 7 as a white solid.
Rf (SiO2/30% EtOAc in hexanes) = 0.53.
point = 171–172 °C dec.

1

Melting

H(500 MHz, CDCl3): δ 7.64 (d,

1H, Ar-H, J = 2.5 Hz), 7.62 (d. 1H, Ar-H, J = 2.5), 6.19 (s, 1H, =C-H).

13

C NMR

(125 MHz, CDCl3): 158.9, 152.5, 148.3, 133.5, 129.9, 123.3, 121.9, 117.1, 101.6.
HRMS (ESI/TOF): calcd for C9H4Cl2N3O2 [M + H]+ 255.9675, found 255.9675.

General procedure for the azide-alkyne ligation reactions leading to the
formation of 4-(4-substituted-1H-1,2,3-triazol-1-yl)-coumarin derivatives.
The CuAAC reactions of various 4-azidocoumarin derivatives (R1 = H,
R2 = H, R3 = H) as follows. As a representative procedure, into a long (6 inch)
screw-cap vial equipped with a stirring bar, were placed 4-azidocoumarin
(37.4 mg, 0.2 mmol, 1 equiv) and CH2Cl2 (0.55 mL) and CH3OH (0.12 mL) and
[Cu(CH3CN)4]PF6 (7.5 mg, 0.02 mmol, 0.10 equiv). The mixture was stirred at
room temperature to dissolve the reactants, then phenylacetylene (26 µL,
0.24 mmol, 1.2 equiv) was pipetted into the reaction mixture.

The vial was

capped and placed in a sand bath maintained at 50 °C, and left stirring overnight.
TLC (SiO2/30% EtOAc in hexanes) showed complete reaction of the
4-azidiocoumarin after 24 h. The mixture was partitioned between CH2Cl2 and
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brine.

The organic layer was separated, dried over anhydrous Na2SO4, and

transferred to a round bottom flask. To this 200–300 mesh silica gel was added
and the solvent was evaporated under reduced pressure. The silica gel with the
adsorbed reaction mixture was loaded onto a 200–300 mesh silica gel column and
eluted with a mixture of EtOAc in hexanes. Fractions containing pure material
were combined, evaporated under reduced pressure, and vacuum dried.

All

4-triazolyl coumarins were synthesized in a similar manner and any deviations
from this procedure are noted under the individual compound headings.
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4-(4-Phenyl-1H-1,2,3-triazol-1-yl)-coumarin (8).

Chromatography using

gradient elution with 25-35% EtOAc in hexanes gave 55 mg
(95% yield from a 0.2 mmol reaction) of compound 8 as a light
yellow solid.

Rf (SiO2/30% EtOAc in hexanes) = 0.20.

Melting point = 178–180 °C (lit.13 166–168 °C). 1H (500 MHz,
CDCl3): δ 8.22 (s, 1H, triazolyl-H), 7.98 (d, 1H, Ar-H, J = 8.3 Hz), 7.93 (d, 2H,
Ar-H, J = 7.3 Hz), 7.68 (t, 1H, Ar-H, J = 7.8 Hz), 7.49 (m, 3H, Ar-H, J = 7.7 Hz),
13

7.41 (m, 2H, Ar-H), 6.62 (s, 1H, =C-H).

C NMR (125 MHz, CDCl3): δ 159.7,

154.2, 148.5, 146.6, 133.5, 129.1, 129.1, 129.0, 126.0, 125.7, 125.0, 120.3, 117.5,
114.3, 109.6. HRMS (ESI/TOF): calcd for C17H12N3O2 [M + H]+ 290.0924,
found 290.0934.
4-(4-(p-Tolyl)-1H-1,2,3-triazol-1-yl)-coumarin (9).

Chromatography using

gradient elution with 20-30% EtOAc in hexanes to yield 53 mg
(87% yield from a 0.2 mmol reaction) of compound 9 as a
white solid. Rf (SiO2/30% EtOAc in hexanes) = 0.28. Melting
point = 198–199 °C dec (lit13 181–183 °C).

1

H (500 MHz,

CDCl3): δ 8.20 (s, 1H, triazolyl-H), 8.00 (d, 1H, Ar-H,
J = 8.3 Hz), 7.82 (d, 2H J = 7.8Hz), 7.69 (t, 1H, Ar-H, J = 7.8 Hz), 7.48 (d, 1H,
Ar-H, J = 8.3 Hz), 7.38 (t, 1H, Ar-H, J = 7.6 Hz), 7.30 (d, 2H, Ar-H, J = 7.8 Hz),
6.61 (s, 1H, =C-H), 2.42 (s, 3H, CH3).

13

C NMR (125 MHz, CDCl3): δ 159.8,

154.3, 148.7, 146.7, 139.2, 133.5, 129.8, 126.2, 125.9, 125.7, 125.0, 119.8, 117.5,
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114.3, 109.5, 21.4. HRMS (ESI/TOF): calcd for C18H14N3O2 [M + H]+ 304.1081,
found 304.1071.
4-(4-(4-Methoxyphenyl)-1H-1,2,3-triazol-1-yl)-coumarin (10).

The reaction

conditions for this compound were the same in all aspects
except that the reaction was conducted at 80 °C.
Chromatography using gradient elution with 30–40%
EtOAc in hexanes to yield 51 mg (72% yield from a
0.2 mmol reaction) of compound 10 as a white solid.
Rf SiO2/30% EtOAc in hexanes) = 0.21. Melting point = 196–198 °C dec (lit13
183–185 °C).

1

H (500 MHz, CDCl3): δ 8.14 (s, 1H, triazolyl-H), 8.02 (d, 1H,

Ar-H, J = 7.8 Hz), 7.87 (d, 2H, Ar-H, J = 8.3 Hz), 7.70 (t, 1H, Ar-H, J = 7.8 Hz),
7.49 (d, 1H, Ar-H, J = 8.3 Hz), 7.39 (t, 1H, Ar-H, J = 7.6 Hz), 7.03 (d, 2H, Ar-H,
J = 8.8 Hz), 6.62 (s, 1H, =C-H), 3.88 (s, 3H, -OCH3).

13

C NMR (125 MHz,

CDCl3): δ 160.3, 159.8, 154.3, 148.5, 146.7, 133.5, 129.4, 127.4, 125.8, 125.0,
121.6, 119.2, 117.6, 114.5, 109.4, 55.4. HRMS (ESI/TOF): calcd for C18H14N3O3
[M + H]+ 320.1030, found 320.1039.
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4-(4-(Pyridin-3-yl)-1H-1,2,3-triazol-1-yl)-coumarin

(11).

The

reaction

conditions for this compound were the same in all aspects
except that the reaction was conducted at room temperature
(25 °C). Chromatography using gradient elution with 20–30%
EtOAc in hexanes to yield 55 mg (95% yield from a 0.2 mmol
reaction) of compound 11 as a white solid.

Rf (SiO2/30%

EtOAc in hexanes) = 0.28. Melting point = 145–146 °C. 1H (500 MHz, CDCl3):
δ 8.62 (m, 2H, Ar-H and triazolyl-H), 8.26 (d, 1H, Ar-H, J = 8.3 Hz), 7.92 (dd,
1H, Ar-H, J = 1.5, 8.3 Hz), 7.85 (t, 1H, Ar-H, J = 1.7, 7.7 Hz), 7.68 (t, 1H, Ar-H,
J = 1.3, 7.8 Hz), 7.48 (dd, 1H, Ar-H, J = 1.0, 8.3 Hz), 7.37 (t, 1H, Ar-H,
J = 7.7 Hz), 7.32 (ddd, 1H, Ar-H, J = 1.2, 4.9, 7.6 Hz), 6.67 (s, 1H, =C-H).
C NMR (125 MHz, CDCl3): δ 159.6, 154.2, 149.6, 148.9, 148.7, 146.6, 137.2,

13

133.5, 125.3, 125.0, 123.6, 122.9, 120.6, 117.5, 114.2, 110.0. HRMS (ESI/TOF):
calcd for C16H12N4O2 [M + H]+ 291.0877, found 291.0888.
4-(4-(Thiophen-3-yl)-1H-1,2,3-triazol-1-yl)coumarin (12).

Chromatography

using gradient elution with 15-20% EtOAc in hexanes gave
53 mg (89% yield from a 0.2 mmol reaction) of compound 12
as a white solid. Rf (SiO2/30% EtOAc in hexanes) = 0.33.
Melting point = 185–187 °C dec. 1H (500 MHz, CDCl3): δ 8.13
(s, 1H, triazolyl-H), 7.98 (d, 1H, Ar-H, J = 8.3 Hz), 7.87 (d, 1H,
thienyl-H, J = 2.0 Hz), 7.70 (t, 1H Ar-H, J = 7.8 Hz), 7.55 (d, 1H, thienyl-H,
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J = 5.1 Hz), 7.48 (m, 2H, Ar-H and thienyl-H), 7.39 (t, 1H, Ar-H, J = 7.8 Hz),
6.62 (s, 1H, =C-H).

C NMR (125 MHz, CDCl3): δ 159.7, 154.3, 146.7, 144.7,

13

133.6, 130.1, 127.0, 125.7, 125.7, 125.1, 122.7, 119.9, 117.6, 114.4, 109.6.
HRMS (ESI/TOF): calcd for C15H10N3O2S [M + H]+ 296.0488, found 296.0488.
6-Bromo-4-(4-(2,4,5-trimethylphenyl)-1H-1,2,3-triazol-1-yl)coumarin

(13).

Chromatography using gradient elution with 15–25%
EtOAc in hexanes to yield 55 mg (67% yield from a
0.2 mmol reaction) of compound 13 as a pale yellow
solid.

Rf (SiO2/30% EtOAc in hexanes) = 0.40.

Melting point = 206–207 °C dec.

1

H (500 MHz,

CDCl3): δ 8.29 (d, 1H, Ar-H, J = 2.4 Hz), 8.08 (s, 1H, triazolyl-H), 7.77 (dd, 1H,
Ar-H, J = 2.2, 8.8 Hz), 7.67 (s, 1H, Ar-H), 7.36 (d, 1H, Ar-H, J = 8.8Hz), 7.11 (s,
1H, Ar-H), 6.63 (s, 1H, =C-H), 2.49 (s, 3H, CH3), 2.32 (s, 3H, CH3), 2.30 (s, 3H,
CH3).

13

C NMR (125 MHz, CDCl3): δ 159.1, 153.2, 148.2, 145.5, 137.7, 136.4,

134.6, 132.8, 132.5, 130.0, 128.6, 125.4, 121.6, 119.2, 117.9, 115.8, 109.7, 20.9,
19.5, 19.2. HRMS (ESI/TOF): calcd for C20H17BrN3O2 [M + H]+ 410.0499,
found 410.0485.
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6-Methyl-4-(4-(thiophen-3-yl)-1H-1,2,3-triazol-1-yl)coumarin

(14).

Chromatography using gradient elution with 15–20% EtOAc
in hexanes gave 55 mg (89% yield from a 0.2 mmol reaction)
of compound 14 as a white solid. Rf (SiO2/30% EtOAc in
hexanes) = 0.54. Melting point = 209–210 °C.

1

H (500

MHz, CDCl3): δ 8.11 (s, 1H, triazolyl-H), 7.87 (d, 1H,
thienyl-H, J = 2.9 Hz), 7.73 (s, 1H, Ar-H), 7.56 (dd, 1H, thienyl-H,
J = 1.2, 5.1 Hz), 7.46 (m, 2H, Ar-H, thienyl-H), 7.38 (d, 1H, Ar-H, J = 8.3 Hz),
6.58 (s, 1H, =C-H), 2.42 (s, 3H, -CH3).

C NMR (125 MHz, CDCl3): δ 160.0,

13

152.5, 146.7, 144.6, 135.7, 135.1, 134.7, 130.1, 127.2, 125.6, 125.2, 122.6, 119.9,
117.3, 114.0, 109.6, 21.1. HRMS (ESI/TOF): calcd for C16H12N3O2S [M + H]+
310.0645, found 310.0653.
4-(4-(Cyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-yl)-7-methylcoumarin

(15).

Chromatography using gradient elution with 15–20%
EtOAc in hexanes gave 53 mg (86% yield from a 0.2 mmol
reaction) of compound 15 as a white solid. Rf (SiO2/30%
EtOAc in hexanes) = 0.53. Melting point = 208–210 °C.
1

H (500 MHz, CDCl3): δ 7.84 (m, 2H, triazolyl-H, Ar-H),

7.23 (s, 1H, Ar-H), 7.15 (d, 1H, Ar-H, J = 8.3 Hz), 6.72 (m, 1H, =C-H), 6.45 (s,
1H, =C-H), 2.48 (s, 3H, CH3), 2.42 (m, 2H, CH2), 2.25 (m, 2H, CH2), 1.80 (m,
2H, CH2), 1.70 (m, 2H, CH2).

13

C NMR (125 MHz, CDCl3): δ 160.2, 154.3,
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149.9, 146.8, 145.1, 127.3, 126.1, 125.9, 125.4, 118.7, 117.5, 111.7, 107.6, 26.2,
25.3, 22.2, 21.9, 21.7.

HRMS (ESI/TOF): calcd for C18H18N3O2 [M + H]+

308.1394, found 308.1397.
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CONCLUSION
A successfully and safe two step one pot process for the azidization of
4-hydroxycoumarin was demonstrated in this thesis. The process involved the
initially transformation of 4-hydroxycoumarin to its 4-benzotriazolyloxycoumarin
with the used of inexpensive reagents like BOP, DBU and THF. Using this
reaction scheme the formation of the benzotriazole ether bond was followed by
addition elimination with sodium azide providing the azidization of the
compounds.
The copper catalyzed alkyne azide cycloaddition were optimized by
screening

various

copper

catalysts

and

tetrakis(acetonitrile)copper(I)

hexafluorophosphate, which contributed to better results in this reaction. Once
the

reaction

with

good

was
to

optimized,
excellent

various
yields

1,2,3-triazoles

with

the

were

formation

synthesized
of

solely

1,4 substituted 1,2,3 triazoyl coumarin compounds. As previously stated in this
paper, other authors have worked in the synthesis of leaving groups in the
4 position of coumarin compounds. However, synthesis of leaving groups such as
4-chloro and 4-sulfonate do not offer the versatility and ease of the two step one
pot reaction that we have presented in this thesis.
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